Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine

► We developed a novel HIV-1 clade C consensus envelope DNA vaccine (pEY3E1-C). ► pEY3E1-C is up to three times more potent in driving CTL responses. ► pEY3E1-C increases the breadth of induced cellular immune responses as well.